BFRI Biofrontera Inc. logo

BFRI Biofrontera Inc.

Healthcare
$0.81+3.61%ClosedMarket Cap: $10.3M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

PEG

P/B

1.55

P/S

0.24

EV/EBITDA

-1.42

DCF Value

$-29.82

FCF Yield

-90.1%

Div Yield

0.0%

Margins & Returns

Gross Margin

82.8%

Operating Margin

-20.6%

Net Margin

-25.7%

ROE

-476.7%

ROA

-44.7%

ROIC

-62.1%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$10.1M$-4.8M$
Q4 null$17.1M$5.6M$
FY null$41.7M$-10.5M$
Q3 null$7.0M$-6.6M$

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

1 Strong Buy2 Buy0 Hold0 Sell0 Strong Sell
BenchmarkSpeculative Buy
2026-05-19

Trading Activity

Insider Trades

View All
Weber Kevin Danieldirector
SellFri Mar 06
Luebbert Hermanndirector, officer: CEO & Chairman
SellFri Mar 06
Luebbert Hermanndirector, officer: CEO & Chairman
SellFri Mar 06
Leffler Eugene Frederickofficer: Chief Financial Officer
SellFri Mar 06
Leffler Eugene Frederickofficer: Chief Financial Officer
SellFri Mar 06

Company Info

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Country

US

Exchange

Beta

0.91

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Peers